Meet ApplyKite Twin, the application assistant that learns with you
Meet your Twin, it learns with you
Your Twin learns with you
Launch week codes:30% off annual Pro20% off monthly Pro
Ends in00h00m00s
Ends in00h00m00s
Georgia Salanti
Has grant
Research Interests
Explore related searches
Recent Grants
Grant: Close
MetaInsight and CINeMA: Reproducible evidence for clinical decision-making
Open Date: 2024-09-01
Close Date: 2026-08-01
Grant: Close
Global Alliance for Living Evidence on aNxiety, depressiOn and pSychosis (GALENOS)
Open Date: 2023-01-01
Close Date: 2025-12-01
Grant: Close
Expert workshop on risks of bias and reporting of prevalence studies in epidemiology
Open Date: 2022-07-01
Close Date: 2022-09-30
Grant: Close
A continuously updated meta-ecological study of the effects of the COVID-19 pandemic on mental health, alcohol/substance abuse and violence in the general population.
Open Date: 2020-10-01
Close Date: 2022-09-30
Grant: Close
Next Generation Health Technology Assessment to support patient-centred, societally oriented, real-time decision-making on access and reimbursement for health technologies throughout Europe
Open Date: 2019-01-01
Close Date: 2023-12-31
Articles (4)
Year:
2026
Year:
2025
Year:
2025
Network meta-analysis has been used to answer a range of clinical questions about the preferred intervention for a given condition. Although the effectiveness and safety of pharmacological agents depend on the dose administered, network meta-analysis applications typically ignore the role that drugs dosage plays in the results. This leads to more heterogeneity in the network. In this paper, we present a suite of network meta-analysis models that incorporate the dose–effect relationship using restricted cubic splines. We extend existing models into a dose–effect network meta-regression to account for study-level covariates and for groups of agents in a class-effect dose–effect network meta-analysis model. We apply our models to a network of aggregate data about the efficacy of 21 antidepressants and placebo for depression. We find that all antidepressants are more efficacious than placebo after a certain dose. Also, we identify the dose level at which each antidepressant's effect exceeds that of placebo and estimate the dose beyond which the effect of antidepressants no longer increases. When covariates were introduced to the model, we find that studies with small sample size tend to exaggerate antidepressants efficacy for several of the drugs. Our dose–effect network meta-analysis model with restricted cubic splines provides a flexible approach to modelling the dose–effect relationship in multiple interventions. Decision-makers can use our model to inform treatment choice.
Year:
2022
Collaborators (5)
Ian White
Professor at Institute of Clinical Trials and Methodology (ICTM)
University College London
Graham Peter Herbison
University of Otago
Areti Angeliki Veroniki
Associate Professor
Brown University
Alexandra Bannach-Brown
Charité - Universitätsmedizin Berlin
Ulf Toelch
Berlin Institute of Health at Charité - Universitätsmedizin Berlin
Make your next move.
Prepare your application
Review drafts before you send them.